Your browser is no longer supported. Please, upgrade your browser.
FBRX Forte Biosciences, Inc. daily Stock Chart
Forte Biosciences, Inc.
Index- P/E- EPS (ttm)-28.55 Insider Own20.70% Shs Outstand3.65M Perf Week-12.88%
Market Cap369.50M Forward P/E- EPS next Y-1.87 Insider Trans0.00% Shs Float3.46M Perf Month-17.24%
Income-66.10M PEG- EPS next Q-0.54 Inst Own60.90% Short Float7.07% Perf Quarter65.84%
Sales- P/S- EPS this Y-10.10% Inst Trans9.54% Short Ratio3.08 Perf Half Y94.73%
Book/sh6.82 P/B5.10 EPS next Y74.50% ROA-181.40% Target Price- Perf Year257.06%
Cash/sh- P/C- EPS next 5Y- ROE-459.20% 52W Range6.33 - 53.99 Perf YTD334.61%
Dividend- P/FCF- EPS past 5Y-27.50% ROI- 52W High-35.64% Beta0.19
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin- 52W Low448.97% ATR4.27
Employees5 Current Ratio8.20 Sales Q/Q- Oper. Margin- RSI (14)40.11 Volatility8.73% 9.80%
OptionableYes Debt/Eq0.00 EPS Q/Q12.20% Profit Margin- Rel Volume0.65 Prev Close34.76
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume79.42K Price34.75
Recom1.70 SMA20-20.51% SMA50-2.58% SMA20059.67% Volume44,781 Change-0.03%
Aug-28-20Upgrade Chardan Capital Markets Neutral → Buy $45
Aug-25-20Initiated Truist Buy $70
Sep-29-20 09:00AM  
Sep-16-20 08:48AM  
Sep-09-20 04:01PM  
Aug-25-20 08:30AM  
Aug-10-20 04:00PM  
Aug-03-20 09:00AM  
Jul-28-20 08:30AM  
Jun-18-20 08:30AM  
Forte Biosciences Inc. operates as a clinical-stage dermatology company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company is based in Torrance, California.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.